Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
letolizumab (BMS-986004) / BMS
NCT03605927: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease	Completed	1	45	US	BMS-986004, Anti-CD40L Domain Antibody, Sirolimus, Standard of Care, SIR, Tacrolimus, TAC	H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb	Graft-versus-host-disease, GVHD, GVHD, Acute	09/23	09/23